Mankind Pharma Limited has informed the Exchange about Transcript

Mankind Pharma shared its Q1 FY26 earnings call transcript. Total revenue grew 24.5% year-on-year to Rs. 3,570 crores, with domestic revenue up 19% (10% organic) and international revenue up 81% to Rs. 469 crores (single-digit organic), boosted by BSV consolidation. Reported EBITDA margin stood at 23.8%, a 120 bps adjusted decline year-on-year, driven by a 130 bps drop in gross margins to 70.5% due to unfavorable sales mix and inventory-related accruals. Profit after tax fell 17.4% to Rs. 445 crores on higher finance costs and depreciation from BSV, though cash EPS rose slightly to Rs. 15.9. The company maintained its full-year EBITDA margin guidance of 25-26% and gross margin guidance of above 70%, while reaffirming BSV growth guidance of 18-20%. Net debt reduced to Rs. 5,249 crores with the net debt-to-EBITDA ratio improving to 1.6x, and a plan to repay Rs. 2,000 crores of acquisition debt in FY26 was outlined. An interim dividend of Rs. 1 per share was declared.